IO-120/Etimumotide

N/A

Report date: 2026/04/28 20:00:22

Base Information

Drug NameIO-120/Etimumotide
Drug Alias Namedual PD-L1-derived peptide vaccine/PD-L2-derived peptide vaccineIO-120/IO-103IO-120+IO-103
ClassificationVaccines > Application > Therapeutic vaccineVaccines > Development/production technology > Synthetic peptide vaccineVaccines > Vaccine type > Combination vaccine
Mechanisms of ActionImmunostimulantsProgrammed death-ligand 1 modulatorsProgrammed death-ligand 2 modulators
TargetsProgrammed death-ligand 1Programmed death-ligand 2
Therapy Area/IndicationsLeukemia, Lymphocytic, Chronic, B-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryDenmark
CombinationsYes IO-120Etimumotide
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesIo Biotech Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesIo Biotech Aps
Active IndicationsN/A
Inactive IndicationsLeukemia, Lymphocytic, Chronic, B-Cell

Other Information

ATC CodeN/A
Related LinksN/A